secwatch.observer — SEC 8-K summary
======================================

Issuer:     MoonLake Immunotherapeutics (MLTX)
CIK:        0001821586
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001821586-24-000007
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MoonLake FY 2023 net loss $44.1M; cash $511M; sonelokimab Phase 3 prep advances
-------------------------------------------------------------------------------

- Cash, cash equivalents and short-term marketable debt securities $511.0M at Dec 31, 2023, up from $496M at Sep 30, 2023.
- Net loss for FY 2023 $44.1M, improved from $64.5M in FY 2022.
- R&D expenses $31.8M in FY 2023, down from $42.0M in FY 2022.
- Completed positive Phase 2 data for sonelokimab in HS and PsA; FDA/EMA feedback supports Phase 3 VELA program in HS.
- Raised $85M gross proceeds from at-the-market offerings; cash runway expected to end of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821586/000182158624000007/0001821586-24-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821586/000182158624000007/mnlk-20240229.htm
  HTML page:      https://secwatch.observer/filing/0001821586-24-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer